CHI’s Center for Translational Research (CTR) is a state-of-the-art research and development laboratory, and an integral part of CHI’s commitment to incorporating personalized medicine into cancer care.
“Personalized medicine” is an emerging practice that uses a patient’s genetic profile to guide decisions about the prevention, diagnosis and treatment of disease. Knowledge of a patient’s genetic profile can help doctors tailor medical treatment to the unique characteristics of each patient. They can also group patients into subpopulations according to their susceptibility to a particular disease or their response to a specific treatment.
The CTR leverages CHI’s network of more than 70 community hospitals to promote research and treatments that are personalized not only by disease or tumor type, but by a patient’s unique genetic profile. CHI’s cancer centers collect cancerous and normal tissues from newly diagnosed patients who consent to the procedure. The tissues are sent to the CTR, which stores them for use by researchers across the country who are working to advance our understanding of cancer.